Tech Company Financing Transactions
Caravel Bio Funding Round
Caravel Bio closed a $1.2 million funding round on 10/28/2026. Investors included National Science Foundation.
Transaction Overview
Company Name
Announced On
10/28/2026
Transaction Type
Debt
Amount
$1,200,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4640 South Macadam Avenue 130D
Portland, OR 97239
USA
Portland, OR 97239
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Caravel Bio has built a new data engine for biomolecular engineering, dramatically increasing the scale and speed of generating data. The platform tests millions of protein designs in parallel at a fraction of a cent per experiment, versus tens of dollars with conventional methods, providing the data AI-driven biology has been missing. The company's Artificial Evolution� technology combines cell-free protein synthesis, microfluidic droplets, and bacterial spore display to supercharge biomolecular engineering, so labs can generate the data AI needs to design proteins nature never built.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Trevor Nicks
Chief Information Officer
Agneya Bhushan
Chief Scientific Officer
Emily Bowman
Chief Technical Officer
Michal Jastrzebski
VP - Engineering
Rick Sayler
Browse more venture capital transactions:
Prev: 10/28/2026: Archera venture capital transaction
Next: 10/28/2026: Firehawk Aerospace venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs